Lu Rahman looks at the drug repurposing market. How attractive a proposition is it financially? More than ever the world is watching drug development and is aware of the time it takes to get a drug to market. The 10-15 years that this can involve is costly, so unsurprisingly,… Read More
With COVID-19 taking centre stage in global drug discovery, Lu Rahman looks at opportunities ahead for the sector and where attention might be focussed going forward. It is clear from the current pandemic that opportunities arise within drug discovery and development when we don’t always expect… Read More
By Ibis Sanchez-Serrano and Rathnam Chaguturu Mitigation of COVID-19 pandemic requires a combination of effective epidemiological policies and the discovery/development of powerful drugs against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) that causes this disease. This article examines the major initiatives being explored at the… Read More
By Dr Jamie Freeman Base editing is a potentially transformative technology for engineering DNA in cells that has the potential to generate knockouts or correct certain errors or mutations in the DNA for applications such as cell or gene therapies. Compared with currently-available gene editing… Read More
THE COVID-19 RACE how mouse models will help researchers cross the finish line By Dr Megan MacBride The emergence of SARS-CoV-2 virus and the disease it causes, COVID-19, have fuelled significant shifts in preclinical research across the globe. Amid the worldwide health emergency created by high… Read More
By Dr Karin Bottcher High content screening (HCS) has played a significant role in infectious disease research and drug discovery to date and can be a strong tool in the age of COVID-19 and beyond. With a focus on viral diseases, this article… Read More
By Dr Ross Macdonald Cell-based therapies are being widely recognised for their potential to treat a variety of medical conditions, but they face major obstacles toward commercialisation. Traditionally, they have been difficult and expensive to make in large quantities. Read More
Honing in on perfect targeting By Dr Samantha Zaroff Volume 21 Issue 3 – Summer 2020 The pros and cons of different delivery modalities for personalised cancer vaccines. Introducing neoantigens directly into a patient in order to elicit an anti-tumour killing immune response is known… Read More
The COVID-19 antiviral race: we’re all in this together By Uduak Grace Thomas In response to the COVID-19 pandemic, international scientists from academia and industry have pooled their expertise and resources to identify candidate compounds that inhibit the activity of the SARS-CoV-2 main protease, in order to develop… Read More
The CELL CULTURE innovations increasing drug discovery success By Helen Stewart-Miller and Abby George Volume 21 Issue 3 – Summer 2020 ‘Fail early, fail fast’ has been a mantra in the pharmaceutical industry for several years and directly impacts the overall strategy of many drug discovery and development… Read More
The Personalized Medicine Coalition The Personalized Medicine Coalition (PMC), representing a broad spectrum of academic, industrial, patient, provider, and payer communities, seeks to advance the understanding and adoption of personalized medicine concepts and products for the benefit of patients. As part of its… Read More
Stem Cell Differentiation By Dr Lilian Hook Stem cells are extraordinary cells, capable of both self-renewal and differentiation to mature somatic cells in vivo and in vitro (1,2). They have many features and advantages which could revolutionise drug development and healthcare applications. Read More
Targeting Energy Metabolism for Cancer Therapeutic Discovery using Agilent Seahorse XF Technology Sponsored by Agilent This white paper discusses targeting energy metabolism for cancer therapeutic discovery using Agilent Seahorse XF technology. Abstract Altered energy metabolism is now recognized as a driver… Read More
Advanced Therapeutic Antibody Discovery with Multiplexed Screening Sponsored by Sartorius Antibody-based therapeutics are the fastest growing and most successful therapeutic modality for treating diseases such as cancer, cardiovascular disease, autoimmune disorders and infectious disease. It is predicted that by the year 2020 there will be 70… Read More
PhoreMost enters multi-project drug discovery collaboration with Otsuka Pharmaceutical. PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has entered into a multi-project collaboration with Otsuka Pharmaceutical Co., the world-leading pharmaceutical company dedicated to the research and development of highly-innovative… Read More
Miltenyi Biotec has launched its SARS-CoV-2 PepTivator Peptide Pools, a new addition to its PepTivator Portfolio specifically developed to help researchers currently investigating COVID-19 Based on decades worth of experience in developing products for virus-specific T cell research, SARS-CoV-2 PepTivator Peptide Pools work by stimulating T cells specific… Read More